Positive data reported from phase 2b study of gusacitinib in patients with chronic hand eczema

Study (n=97) of this oral JAK and spleen tyrosine kinase inhibitor noted dose-dependent, improvement in efficacy endpoints relative to placebo (decrease of 69%; p<0.005 in mean modified total lesion severity score from baseline with 80mg vs.49% for 40mg and 33% for placebo)

Source:

Biospace Inc.